{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. \"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.","id":"OG000","title":"Everolimus and Letrozole"},{"description":"Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.","id":"OG001","title":"Tamoxifen and Medroxyprogesterone Acetate"}],"paramType":"NUMBER","populationDescription":"Eligible and treated participants. One participant in arm II was not treated. Participant flow contains all eligible participants.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death , up to 3 years.","title":"Frequency of Response","type":"PRIMARY","unitOfMeasure":"Number of participants"}